M Roselli, C U Casciani, F Guadagni, O Buonomo, B Iorio, A Diodati, V Vittorini, J W Greiner, D Colcher, J Schlom
{"title":"Monoclonal antibodies in the management of carcinoma patients.","authors":"M Roselli, C U Casciani, F Guadagni, O Buonomo, B Iorio, A Diodati, V Vittorini, J W Greiner, D Colcher, J Schlom","doi":"10.1007/BF02987190","DOIUrl":null,"url":null,"abstract":"<p><p>The use of monoclonal antibodies (MAbs) in the clinical management of carcinoma patients is reported in the present review. Among the various MAbs generated, MAb B72.3 (LTIB, National Cancer Institute, U.S.A.) has been extensively used in clinical trials either for antigen identification (TAG-72) in sera, or for tumor localization in carcinoma patients. Serum assay results, in colorectal cancer patients, showed the usefulness of the MAb B72.3 in monitoring the clinical course of the malignant disease. Its specific tumor localization (70% of the biopsy specimens) and the immunoscintigraphy studies, after in vivo administration, have also been discussed. The positive results obtained, markedly contributed in the development of a new intraoperative methodology termed \"radioimmunoguided surgery\".</p>","PeriodicalId":77257,"journal":{"name":"Medical oncology and tumor pharmacotherapy","volume":"8 4","pages":"223-8"},"PeriodicalIF":0.0000,"publicationDate":"1991-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/BF02987190","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Medical oncology and tumor pharmacotherapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/BF02987190","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 2
Abstract
The use of monoclonal antibodies (MAbs) in the clinical management of carcinoma patients is reported in the present review. Among the various MAbs generated, MAb B72.3 (LTIB, National Cancer Institute, U.S.A.) has been extensively used in clinical trials either for antigen identification (TAG-72) in sera, or for tumor localization in carcinoma patients. Serum assay results, in colorectal cancer patients, showed the usefulness of the MAb B72.3 in monitoring the clinical course of the malignant disease. Its specific tumor localization (70% of the biopsy specimens) and the immunoscintigraphy studies, after in vivo administration, have also been discussed. The positive results obtained, markedly contributed in the development of a new intraoperative methodology termed "radioimmunoguided surgery".
本文综述了单克隆抗体(mab)在肿瘤患者临床治疗中的应用。在产生的各种单克隆抗体中，单克隆抗体B72.3 (LTIB, National Cancer Institute, U.S.A.)已广泛用于临床试验，用于血清抗原鉴定(TAG-72)或癌症患者的肿瘤定位。在结直肠癌患者中，血清检测结果显示单克隆抗体B72.3在监测恶性疾病的临床病程方面的有效性。在体内给药后，其特异性肿瘤定位(活检标本的70%)和免疫显像研究也进行了讨论。所获得的积极结果显著促进了一种称为“放射免疫引导手术”的新术中方法的发展。
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
